

Immunogenicity and Safety of Gamma, Omicron BA.4/5 and Bivalent SARS-CoV-2 RBD-based Protein Booster Vaccines in Adults Previously Immunized with Different Vaccine Platforms: a Phase II/III, Randomized, Clinical Trial.

Authors:

Gonzalo Perez-Marc^{1,2*}; Lorena M. Coria^{3,4*}; Ana Ceballos⁵; Juan Manuel Rodriguez⁶; Mónica E. Lombardo^{7,8}; Laura Bruno^{3,4}; Federico Páez Córdoba^{3,4}; Clara G. Fascetto Cassero^{3,4}; Melina Salvatori⁵; Mayra Rios Medrano^{3,4}; Fabiana Fulgenzi^{3,4}; María F. Alzogaray⁷; Analía Mykietiuik⁹; Ignacio Leandro Uriarte^{10,11}; Nicolás Itcovici¹²; Tomás Smith Casabella¹³; Gonzalo Corral¹⁴; Miriam Bruno¹⁵; Oscar Roldán¹⁶; Sebastián A. Nuñez¹⁷; Florencia Cahn¹⁸; Gustavo A. Yerino¹⁹; Alejandra Bianchi²; Virginia Micaela Braem²; Analía Christmann²; Santiago Corradetti²; Martín Claudio Darraidou²; Lucila Di Nunzio²; Tatiana Belén Estrada²; Rocío López Castelo²; Carla Graciela Marchionatti²; Lucila Pitocco²; Virginia Macarena Trias Uriarte²; Cristian Jorge Wood²; Romina Zadoff²; Florencia Bues⁷; Rosa M. Garrido⁷; Laboratorio Pablo Cassará group for ARVAC⁶; Agostina Demaría^{3,4}; Lineia Prado^{3,4}; Celeste Pueblas Castro^{3,4}; Lucas Saposnik^{3,4}; Jorge Geffner⁵; Federico Montes de Oca⁶; Julio C. Vega⁶; Juan Fló⁶; Pablo Bonvehí⁸; Jorge Cassará⁶; Karina A. Pasquevich^{3,4**}; Juliana Cassataro^{3,4**}

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Affiliations:

¹ Hospital Militar Central. Ciudad Autónoma de Buenos Aires, Argentina.

² ARVAC Clinical trial study group. Argentina.

³ Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín (UNSAM) - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), San Martín, Buenos Aires, Argentina.

⁴ Escuela de Bio y Nanotecnologías (EByN), Universidad Nacional de San Martín, San Martín, Buenos Aires, Argentina.

⁵ Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, INBIRS-CONICET, Facultad de Medicina UBA, Buenos Aires, Argentina.

⁶ Laboratorio Pablo Cassará S.R.L, Ciudad Autónoma de Buenos Aires, Argentina.

⁷ Nobeltri S. R. L., Ciudad Autónoma de Buenos Aires, Argentina.

⁸ Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Ciudad Autónoma de Buenos Aires, Argentina.

⁹ Instituto Médico Platense, La Plata, Buenos Aires, Argentina.

¹⁰ Clínica del Niño y la Madre, Mar del Plata, Buenos Aires, Argentina.

¹¹ Escuela Superior de Medicina, Universidad Nacional de Mar del Plata, Mar del Plata, Buenos Aires, Argentina.

¹² Centro de Investigaciones Clínicas Belgrano S.A. Ciudad Autónoma de Buenos Aires, Argentina.

¹³ Investigaciones Clínicas Salta (ICSAL), Ciudad de Salta, Salta, Argentina.

¹⁴ Instituto de Investigaciones Clínicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina.

¹⁵ Vacunar S.A. Ciudad Autónoma de Buenos Aires, Argentina.

¹⁶ Clínica Privada del Sol S.A., Ciudad de Córdoba, Córdoba. Argentina.

¹⁷ Centro Médico Maffei - Investigación Clínica Aplicada. Ciudad Autónoma de Buenos Aires, Argentina.

¹⁸ Fundación Huésped, Ciudad Autónoma de Buenos Aires, Argentina.

¹⁹ FP Clinical Pharma S.R.L., Ciudad Autónoma de Buenos Aires, Argentina.

Corresponding author:

Karina. A. Pasquevich: kpasquevich@iib.unsam.edu.ar and Juliana Cassataro: jucassataro@iib.unsam.edu.ar.

* These authors contributed equally.

** These authors contributed equally.

Abstract

Background: This study (ARVAC-F2-3-002) assessed the immunogenicity, safety, and tolerability of a recombinant booster vaccine (ARVAC) containing the receptor binding domain of the SARS-CoV-2 Spike protein in three different versions: Gamma (ARVAC_{Gamma}), Omicron BA.4/5 (ARVAC_{Omicron}), and Gamma/Omicron Bivalent (ARVAC_{Bivalent}).

Methods: Randomized, double-blind, crossover, placebo-controlled, multicenter (11 centers in Argentina) Phase II/III trial including adult volunteers previously vaccinated against SARS-CoV-2 with ≤ 3 booster doses. Participants were randomized to receive ARVAC_{Gamma} (50 μ g)+placebo and vice-versa (1:1 ratio) (Phase II), and ARVAC_{Gamma} (50 μ g)+placebo, ARVAC_{Omicron} (50 μ g)+placebo, and ARVAC_{Bivalent} (Gamma/Omicron 25 μ g/25 μ g)+placebo and vice-versa (Phase III) (1:1:1:1:1 ratio) 28 days apart. The primary endpoint was the seroconversion rate of neutralizing antibodies compared to placebo. The vaccine immunogenicity was considered acceptable at $>75\%$ seroconversion rate to variants homologous to the antigen contained in the vaccine (prespecified primary endpoint).

Results: Participants (n=2012) (mean 48.2 years, SD 16.7; 48.1% women) were randomized and allocated to ARVAC_{Gamma} (n=232 in Phase II and n=592 in Phase III), ARVAC_{Omicron} (n=594), and ARVAC_{Bivalent} (n=594); 232 in Phase II and 370 in each Phase III group were included in the immunogenicity subset. Seroconversion rates to all SARS-CoV-2 variants were significantly higher after receiving any vaccine than placebo. All vaccine versions met the prespecified primary endpoint in all participants and in those 18–60 years old. In participants >60 years, the ARVAC_{Omicron} and the ARVAC_{Bivalent} met the prespecified primary endpoint, whereas the ARVAC_{Gamma} did not. The ARVAC_{Bivalent}

induced seroconversion rates were significantly higher than 75% across all tested SARS-CoV-2 variants (homologous and heterologous) and age groups. No vaccine-related serious adverse events were recorded; most local and systemic adverse events were grade 1-2.

Conclusion: Booster vaccination with Gamma, Omicron BA.4/5, and Bivalent protein subunit recombinant ARVAC vaccine versions elicited protective neutralizing antibody responses to several SARS-CoV-2 variants, with very low reactogenicity and a favorable safety profile.

Trial registration: NCT05752201

Keywords: Booster; receptor binding domain; recombinant protein vaccine; SARS-CoV-2; variant-adapted vaccine.

Background

Coronavirus disease 2019 (COVID-19) continues to be a global health threat.^{1,2} Public health measures, population immunization, and the development of effective vaccines contributed to decreasing SARS-CoV-2 virus circulation, disease severity, and associated mortality.³ However, vaccine- and infection-induced immunity progressively wanes,^{4,5} and new, highly contagious SARS-CoV-2 variants and subvariants that escape from vaccine-induced immunity continue to emerge.^{5,6} In this scenario, primary vaccination schemes based on the ancestral SARS-CoV-2 variants fail to provide sufficient long-term protection.⁴

To ensure long-term immune memory, the WHO recommends homologous and heterologous booster doses after primary vaccination for protection against severe COVID-19 disease and death.⁷ Of the most common COVID-19 vaccine platforms,

including inactivated viruses, viral vectors, RNA, and recombinant protein subunits, RNA vaccines are the most widely used. However, they are unstable and require storage at freezing temperatures (-20°C or -80°C), limiting their distribution, particularly in low- and middle-income countries.^{5,8} Conversely, recombinant subunit vaccines are more stable and may be stored in coolers, simplifying the storage and distribution logistics. Recombinant protein large-scale production is available, in several countries, enabling local manufacturing and widespread distribution with lower production costs.⁹ Despite the slower development speed of recombinant subunit vaccines compared to other vaccine platforms,⁹ they can also be modified to induce immunity against novel SARS-CoV-2 variants.¹⁰ Given that their safety profile record is well known and has been studied for more than 30 years, protein-based recombinant vaccines may be used in children, in elderly, and pregnant women.¹¹

Argentina has developed and manufactured a recombinant protein subunit vaccine, ARVAC, which has been recently approved.¹² The first version of the vaccine contains the receptor binding domain (RBD) of the spike protein of the SARS-CoV-2 Gamma variant, with K417T, E484K, and N501Y mutations. Preclinical studies demonstrated that the Gamma RBD version is more immunogenic than the ancestral RBD at inducing broader neutralizing antibodies (nAbs) even against distant variants, such as the Omicron BA.5.¹³ In a Phase I trial, the vaccine was safe and elicited a robust and broad nAb response against several SARS-CoV-2 variants.¹⁴

In this work, we present the results of a Phase II/III trial. The study is a randomized, placebo-controlled trial assessing the immunogenicity, safety, and tolerability of Gamma, Omicron BA.4/5, and bivalent versions of the ARVAC vaccine, used as a booster in adult volunteers previously immunized with different SARS-CoV-2 vaccine platforms.

Methods

Study Design, Objectives, Participants, and Oversight

The ARVAC-F2-3-002 study is a multicenter, randomized, double-blind, crossover, placebo-controlled Phase II/III trial evaluating the immunogenicity, safety, and tolerability of a recombinant protein vaccine against SARS-CoV-2 in adult (≥ 18 years) volunteers previously vaccinated against SARS-CoV-2 with ≤ 3 booster doses. Additional inclusion and exclusion criteria are provided in the **Appendix**. Investigators from 11 participating centers in Argentina (listed in the **Appendix**) consecutively recruited volunteers.

The “Centro de Educación Médica e Investigaciones Clínicas – CEMIC” (Buenos Aires, Argentina) is the sponsor. An external, independent data safety monitoring board reviewed safety data. The trial adhered to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (GCP) and the local data protection law (“Ley de protección de datos” 25,326). All participants signed the informed consent form. The National Administration of Drugs, Food, and Medical Technology (*Administración Nacional de Medicamentos, Alimentación y Tecnología Médica*, ANMAT), the CABA Local Ethics Committee (PRIISA, *Plataforma de Registro Informatizado de Investigaciones en Salud de Buenos Aires*), and the Ethics Committee on Clinical Research (CEIC) of the Infectious Studies Center S.A. (*Centro de Estudios Infecciosos*, CEI) - Stambouliau approved the protocol, which was prospectively registered at ANMAT, PRIISA, and clinicaltrials.gov (NCT05752201). The local Ethics Committees that approved the study protocol are listed in the **Appendix**.

Recombinant Protein Vaccines

The vaccine antigen encompassed aminoacids 319R-537K in the RBD of the SARS-CoV-2 Spike protein. Recombinant proteins for the variants Gamma and Omicron BA.4/5 were produced in CHO-S cells.¹⁴ The Laboratorio Pablo Cassará S.R.L. (Buenos Aires, Argentina) manufactured the ARVAC vaccine as a liquid suspension formulation containing 50 µg of recombinant protein in a 0.5 mL vial, adjuvanted with aluminum hydroxide gel (alhydrogel, 0.5 mg).

Randomization and Procedures

Participants were recruited in two stages. In stage 1 (Phase II), participants were randomized into two subgroups at a 1:1 ratio to receive Gamma-based vaccine (ARVAC_{Gamma}) (50 µg) + placebo (group A) and placebo + ARVAC_{Gamma} (50 µg) (group B) 28 days apart. In stage 2 (Phase III), participants were randomized into three groups to receive the ARVAC_{Gamma} (50 µg), the Omicron BA.4/5-based (ARVAC_{Omicron}) (50 µg), and the Bivalent (Gamma/Omicron BA.4/5 25 µg/25 µg, ARVAC_{Bivalent}) vaccine, with two subgroups each, receiving vaccine + placebo (group A) or placebo + vaccine (group B) 28 days apart (1:1:1:1:1 ratio) (Figure S1). Within each group, individuals were assigned to age subgroups (18–60 years and >60 years) and to immunogenicity subsets (**Appendix**).

Assessments were performed during five visits (V): V1 on day 1 (inclusion visit); V2, 14 ±2 days later; V3, 28 ±2 days after V1; V4, 56 ±2 days after V1; and V5, 90 ±2 days after V1. In all groups, the first treatment was administered on V1 and the second on V3.

Immunogenicity Endpoints and Variables

NAbs against Ancestral (Wuhan), Gamma, or Omicron BA.5 SARS-CoV-2 variants were measured on plasma samples obtained before and after first treatment on days 1 (d1) and 14 (d14) respectively and presented as geometric mean titers (GMT); geometric mean fold rises (GMFR) and GMT ratios (GMTR) were calculated. Additionally, titers against the SARS-CoV-2 Ancestral (Wuhan) variant were transformed to IU/mL using a secondary standard calibrated with a WHO international standard.¹⁵ Based on previous studies, a >1030 UI/mL threshold of nAbs was associated with a 90% efficacy against symptomatic infection.¹⁶

The study's primary endpoint was the seroconversion rate 14 days after receiving the vaccine compared to placebo. The vaccine immunogenicity was considered acceptable at seroconversion rate >75% to variants homologous to the antigen contained in the vaccine (prespecified primary endpoint). The threshold for seroconversion was defined as a 4-fold or a 2-fold increase in nAb titers for individuals with "low" or "high" baseline nAb levels against Ancestral SARS-CoV-2 (<949 or \geq 949 IU/mL), respectively. This classification considered a lower nAb increment in individuals with high basal titers and the association of nAb levels \geq 949 IU/mL with high vaccine protection against symptomatic infection.¹⁶ In Phase III, seroconversion rates were analyzed according to age group and vaccine version.

Other immunogenicity endpoints were the comparison of seroconversion rates among vaccine variants and the superiority and inferiority of bivalent vs. monovalent vaccines. Additional secondary and exploratory endpoints and methods are described in the **Appendix**.

Safety Endpoints and Assessments

Safety endpoints were solicited local and systemic adverse events (AEs), registered daily in the participants' diary within seven days after each vaccine dose, and unsolicited local AEs occurring within 20 minutes after administration. AEs were classified according to severity and their relationship to the study medication based on published guidelines.¹⁷ AEs and serious AEs (SAEs) occurring from the first administration until one and six months after the last administration, respectively, were recorded. Additional details are provided in the **Appendix**.

Statistical Analysis

The sample size was calculated based on the ARVAC_{Gamma} vaccine seroconversion rates obtained in a previous Phase I study.¹⁴ For the prespecified primary endpoint, the estimated sample size was 113 participants for each vaccine candidate, considering a 10% dropout rate. To assess the exploratory endpoint of seroconversion superiority of the bivalent vs. the monovalent vaccines, a sample size of 248 participants for each vaccine candidate was calculated (276, considering a 10% dropout rate). For the safety analysis, a sample size of 2014 participants, 232 in Phase II and 1782 in Phase III, was estimated to detect AEs with a 0.1% prevalence, considering a 20% dropout rate. The Appendix includes a detailed description of the sample size calculation.

The primary endpoint (i.e., immunogenicity) was evaluated in the population of participants randomized to immunogenicity subset who received at least one dose of vaccine or placebo using samples for determination of total and nAbs before (d1) and after the first administration (d14) within an appropriate time frame. The safety endpoints were evaluated in all participants who received at least one dose of vaccine or placebo.

Seroconversion rates after vaccine administration were compared to placebo using the Fisher's exact test and to the 75% reference using a Z-test (primary endpoint). NAb titers were compared between vaccine variants using the Kruskal-Wallis and the Dunns tests for multiple comparisons, and between timepoints (d1 vs. d14) using the Wilcoxon test for paired data. Additional statistical methods are included in the **Appendix**. Significance was set at a bilateral $\alpha < 0.05$. Statistical analyses were performed using GraphPad Prism v8.4.2 (GraphPad Software, San Diego, CA) or R version 4.3.2 for MacOS (R Foundation for Statistical Computing, Viena, Austria).

Results

Participants

A total of 2126 volunteers signed the informed consent, 2012 were included (232 in Phase II and 1780 in Phase III) and randomized. All received the first vaccine/placebo administration and 1905 the second; 138 discontinued the study, and 1874 finished the study protocol (Figure 1).

The mean (SD) age was 48.2 (16.7) years; 48.1% were women, 64.7% had previously received a complete vaccination scheme with one booster, and 44.2% had previous diagnostic of COVID-19 (Table 1). The immunogenicity subset included all study participants of Phase II (Table 1) and 1110 participants of Phase III (Table S1).

Seroconversion Rates (Primary Endpoint)

Seroconversion rates to homologous and non-homologous SARS-CoV-2 variants were higher after receiving any vaccine than placebo overall and in the two age groups ($p < 0.0001$ for all comparisons) (Table 2). All vaccine versions met the prespecified

primary endpoint (i.e., seroconversion rate >75% reference for the homologous variant) in all participants and in those 18–60 years old. In participants >60 years, the ARVAC_{Omicron} and the ARVAC_{Bivalent} met the prespecified primary endpoint, whereas the ARVAC_{Gamma} did not. The ARVAC_{Bivalent} induced seroconversion rates were significantly higher than 75% across all tested SARS-CoV-2 variants (homologous and heterologous) and age groups ($p<0.001$). Analyses using normalized antibody titers yielded similar results (Table S2).

Neutralizing Antibody Titers (Secondary Endpoints)

GMTs to Ancestral, Gamma, and Omicron variants increased from d1 to d14 in participants receiving any vaccine ($p<0.0001$ for all comparisons) but not in those receiving placebo overall and in the two age groups (Figure 2). The percentages of participants with >8 GMFR from d1 to d14 are summarized in Table S3.

At day 90 (d90), GMFR remained statistically significant for all vaccine versions and SARS-CoV-2 variants and according to age group (Figures S2) ($p<0.0001$ for all comparisons).

Participants with nAbs to the Ancestral variant >1030 UI/mL increased at d14 for all vaccine versions ($p<0.0001$), with similar results in the two age groups. For ARVAC_{Gamma}, ARVAC_{Omicron}, and ARVAC_{Bivalent} vaccines, percentages raised from 30.8%, 31.2%, and 24.8% to 87.2%, 85.4%, and 87.9%, respectively in participants 18–60 years; in participants >60 years from 40.4%, 47.2%, and 45.1% to 84.4%, 89.8%, and 92.2%, respectively (Figure S3).

Analyses According to Previous Vaccination and COVID-19 Infection (Secondary Endpoints)

GMTs to all SARS-CoV-2 variants increased in participants receiving the ARVAC vaccine regardless of the number of previous booster doses (Figure S4) or the primary vaccine platforms (adenovirus, mRNA, inactivated virus, heterologous vaccination, or virus like particles) (Figures S5-S8). GMTs and GMFRs lacked significant differences according to previous COVID-19 infection (Figure S9).

Seroconversion Rates and nAb Titers According to Vaccine Versions (Exploratory Endpoints)

ARVAC_{Bivalent} was not inferior to ARVAC_{Omicron} and ARVAC_{Gamma} regarding seroconversion rates against the three SARS-CoV-2 variants in all participants and according to age groups ($p < 0.001$) (Table S4). ARVAC_{Bivalent} seroconversion rates were superior to ARVAC_{Gamma}'s against the Omicron variant ($p = 0.001$) and to ARVAC_{Omicron}'s against the Ancestral ($p < 0.001$) and Gamma ($p = 0.013$) variants. In participants aged 18–60 years, ARVAC_{Bivalent} seroconversion rates were superior to ARVAC_{Omicron}'s against the Ancestral variant ($p = 0.006$), and in participants >60 years, they were superior to ARVAC_{Gamma}'s against the Omicron variant ($p = 0.04$) and to ARVAC_{Omicron}'s against the Ancestral and Gamma variants ($p = 0.020$) (Table S5).

An adjusted multivariate analysis confirmed the superiority of ARVAC_{Bivalent} to ARVAC_{Gamma} in seroconversion rates against the Ancestral ($p = 0.030$), Gamma ($p = 0.015$), and Omicron ($p < 0.001$) variants and to ARVAC_{Omicron} against the Ancestral ($p < 0.001$) and Gamma ($p = 0.005$) variants (Tables S6-S8).

Accordingly, the ARVAC_{Bivalent} was not inferior to the ARVAC_{Omicron} and the ARVAC_{Gamma} regarding GMT against the three SARS-CoV-2 variants regardless of age ($p < 0.001$) (Table S9). All vaccine versions induced similar GMTs to the Ancestral and Gamma variants. However, either in all participants or in those >60 years, the ARVAC_{Bivalent} ($p = 0.0002$ and $p = 0.0026$, respectively) and the ARVAC_{Omicron} ($p = 0.0033$ and $p = 0.0105$, respectively) induced higher titers against the Omicron variant than the ARVAC_{Gamma} (Tables S10-S12).

The ARVAC_{Bivalent} induced higher GMFRs than the ARVAC_{Omicron} for Ancestral ($p = 0.0014$) and Gamma ($p = 0.0076$) variants and higher than the ARVAC_{Gamma} for the Omicron variant ($p = 0.0001$) (Table S13).

GMTR analysis showed that the ARVAC_{Bivalent} was superior to the ARVAC_{Gamma} in nAbs responses to Gamma ($p = 0.048$) and to Omicron ($p < 0.001$) variants. The ARVAC_{Bivalent} was superior to the ARVAC_{Omicron} in the nAb response to Ancestral ($p = 0.022$) and to Gamma ($p = 0.013$) variants (Table S14).

Anti-Spike-Specific Antibodies and Mucosal Response (Exploratory Endpoints)

Plasma levels of anti-spike-specific IgG increased (d1 to d14) in participants receiving any vaccine, regardless of age group ($p < 0.0001$) (Figures S10); changes remained significant at d90 ($p < 0.0001$) (Figure S11). Anti-S1-specific IgA in saliva increased in participants receiving any vaccine ($p < 0.0001$) (Figure S12).

NAbs Against New Emerging Virus Variants

The ARVAC_{Bivalent} vaccine booster activity was further studied against new predominant Omicron subvariants that circulated recently in Argentina. GMTs to XBB.1.18 and JN.1

subvariants increased significantly in participants 18-60 years ($p<0.0001$ and $p=0.0015$, respectively) and in participants >60 years ($p=0.0001$ and $p=0.0069$, respectively) (Figure S13). While most participants ($>89\%$) had detectable nAbs titers against Ancestral, Gamma, and Omicron BA.5 variants before vaccination, nAbs to XBB.1.18 and JN.1 were detectable in 50.0% and 18.8% of participants aged 18-60 and in 61.5% and 33.0% of those >60 years, respectively. These percentages increased to 91.7% and 83.3% in participants aged 18-60 and to 100% and 92.3% in participants >60 years after ARVAC_{Bivalent} administration (Figure S13).

Safety

Most local and systemic AEs were Grade 1 and 2 (Table 3), and no SAEs related to the vaccine were reported. The most frequent local AEs were pain and sensitivity/discomfort in the injection site and were more frequent in participants receiving the vaccine than placebo ($p<0.001$) (Table 3). Pain was more frequent after administration of the ARVAC_{Omicron} and ARVAC_{Bivalent} versions ($p<0.001$) (Table S15).

The most frequent systemic AEs were headache and fatigue/tiredness/decay in 12.3% and 11.8% of participants receiving the vaccine respectively, and 9.6% in participants receiving the placebo (Table 3). A description of AEs according to the vaccine version is included in Table S16.

Discussion

This randomized, double-blind, crossover, placebo-controlled Phase II/III trial showed that booster vaccination with Gamma, Omicron BA.4/5, and bivalent versions of the protein subunit recombinant ARVAC vaccine elicited robust antibody responses to SARS-CoV-2 Ancestral, Gamma, and Omicron BA.5 variants in adults, regardless of

primary vaccination platform, and previous SARS-CoV-2 infection. At d14 after vaccination, seroconversion rates to homologous and non-homologous SARS-CoV-2 variants after receiving any vaccine version were higher than placebo. In all participants the three vaccine versions elicited seroconversion rates to homologous SARS-CoV-2 variants >75% reference (prespecified primary endpoint). GMTs against the three SARS-CoV-2 variants significantly increased, and antibody responses persisted for at least 90 days, even in participants >60 years. The nAb levels in IU/mL suggested that the vaccine versions achieved $\geq 90\%$ efficacy against symptomatic infection in 84.4%–92.2% of participants. The bivalent vaccine induced more prominent GMFRs and higher seroconversion rates than monovalent vaccines. Moreover, all vaccine versions increased anti-spike-specific antibody levels in plasma and saliva, with a favorable safety and tolerability profile.

Results from this trial confirmed those from our previous Phase I study, including younger participants (18-55 years) with a variety of primary vaccination schemes.¹⁴ Moreover, the results from this trial support previous studies indicating increased immunogenicity and breadth of a Gamma-variant vaccine compared to the ancestral-variant vaccine.^{13,14}

To our knowledge, few trials have simultaneously assessed and compared the immunogenicity outcomes of several vaccine variants, as showed in this Phase III trial, comparing three vaccine versions.^{18,19} Bivalent Ancestral/Omicron, Alpha/Beta, and Ancestral/Beta recombinant boosters have previously shown robust nAb responses in individuals who had received primary schemes based mostly on mRNA or Adenoviruses,^{18–20} but a bivalent recombinant booster vaccine lacking the Ancestral/Alpha variants remained unassessed. Despite including a lower dose of each monovalent vaccine, the ARVAC_{Bivalent} booster was non-inferior regarding

seroconversion rates and GMTs, and, remarkably, it was superior to the monovalent vaccines against heterologous SARS-CoV-2 variants. Furthermore, ARVAC_{Bivalent} induced seroconversion rates >90% against all SARS-CoV-2 variants in all age groups. Similar results, superiority to monovalent versions against heterologous variants and non-inferiority against homologous variants, were described for a bivalent Omicron BA.5/ancestral SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose.¹⁹

Unlike this trial, the population included in other trials assessing boosting with recombinant protein vaccines were highly homogenous regarding the primary vaccination scheme, mostly based on mRNA (BNT162b2 or mRNA-1273), Ad26, and ChAdOx-1 vaccines.¹⁸⁻²¹ However, at least seven vaccines based on different platforms were applied as primary and booster doses in Argentina when we initiated this study.²² This trial showed robust nAb responses regardless of the previous vaccination scheme (six platforms) and the number of previous booster doses (no booster, one, or two). Hence, the results of this trial were obtained in a large population with no strict selection criteria, reflecting the variety of primary vaccination schemes in Argentina and providing valuable information for applying the ARVAC vaccine in real-world populations. In this regard, an adjusted multivariate analysis revealed the superiority of ARVAC_{Bivalent} compared to ARVAC_{Gamma} or ARVAC_{Omicron} independently of age, sex, number of previous vaccine doses, previous vaccine platform, time since last vaccination, and previous COVID-19 history. Moreover, these results contribute to the increasing evidence that heterologous schedules may provide superior immunogenicity to homologous booster schedules.²³⁻²⁵ Furthermore, this study included participants with and without comorbidities. The WHO includes older individuals (>50-60 years, depending on the country) as high-priority, with

booster doses recommended at 12-month intervals.⁷ Hence, our results provide data on booster responses in relevant populations.

The Omicron BA.4/5 and Gamma antigens in the ARVAC_{Bivalent} contain the main mutations conferring immune evasion and are, therefore, likely to elicit the production of antibodies neutralizing other Omicron subvariants. The immunogenicity of ARVAC_{Bivalent} against Omicron XBB.1.18 and JN.1 subvariants is encouraging, given that these variants contain more immune-evasive mutations than most others detected to date and are predominant in many geographical centers. Nevertheless, it is possible that adapting ARVAC to new emerging variants (i.e., XBB.1.5 or JN.1) would further increase the immunogenicity. Nevertheless, the Omicron BA.4/5 is adapted to the currently circulating SARS-CoV-2 variants (i.e., Omicron subvariants).²⁶ The WHO and the Food and Drug Administration (FDA) recommend that booster doses include an Omicron BA.4/5 component and exclude the Ancestral strain;^{27,28} therefore, the ARVAC vaccine assessed in this study fulfills these recommendations.

ARVAC demonstrated to be safe and as expected for being a protein-based recombinant vaccine induced a very low reactogenic response. Therefore, an alternative vaccine platform with a history of safe and effective use has the potential to benefit public health by providing an additional choice to our region.

One limitation of this study is the short follow-up for immunogenicity. However, in the Phase I study, the nAb titers remained significantly increased even after six¹⁴ and twelve months of vaccine administration (unpublished results). Despite this limitation, this study showed that the ARVAC RBD-based protein vaccine and, particularly, its bivalent version, used as a first, second or third booster, elicited robust, protective, long-lasting antibody responses in participants with a complete vaccination scheme regardless of age, sex, previous vaccine platform, and previous SARS-CoV-2 infection.

Conclusions

Booster vaccination with Gamma, Omicron BA.4/5, and bivalent versions of the protein subunit recombinant ARVAC vaccine elicited protective neutralizing antibody responses to several SARS-CoV-2 variants, including the currently circulating Omicron variant. ARVAC showed very low reactogenicity and a favorable safety profile, as expected for a recombinant protein alhydrogel adjuvanted vaccine. The ARVAC vaccine is a valuable booster option given the recommended administration of booster doses that include Omicron while excluding Ancestral SARS-CoV-2 variants to high-priority populations, the variety of approved primary vaccination schemes, the feasibility and low cost of large-scale recombinant vaccine production, its potential for adaptation, its safety profile, and its feasible widespread distribution.

Declarations

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

J.M.R., L.P.C. Group, F.M.O., J.C.V. and JoC are employees of Laboratorio Pablo Cassará S.R.L., which developed the vaccine. M.E.L. and J.F. are external consultants and received honoraria from Laboratorio Pablo Cassará S.R.L. G.PM has received a research grant from Merck and G.PM, A.B., V.M.B., A.Ch, S.C., M.C.D., L.DN., T.B.N., R.LP., C.G.M., LP, V.M.TU, C.J.W, and R.Z. conduct clinical trials for Pfizer, Merck, Sanofi, and Moderna, Inc. P.B. was investigator in clinical trials of Sinopharm and Janssen COVID-19 vaccines and was Advisory Board Participant for Moderna and Raffo. M.F.A. received honoraria for clinical research from Astra Zeneca, Pfizer, Dompé and Red Insight. N.I. received honoraria for clinical research GSK, Celcuity, Novartis, Genentech, Astra Zeneca, MSD, and Chiesi. S.A.N. received honoraria for clinical research from: GSK, AstraZeneca, Sanofi Aventis, Eli Lilly, NIAID, ATEA Pharmaceuticals and financial help to assist meetings and conferences from GSK, MSD, and Sanofi. O.R. was principal investigator in a clinical study of Merck. R.M.G. and F.B. are employees from Nobeltri S.R.L that offers services to Laboratorio Pablo Cassará S.R.L. All other authors declare no competing interests.

Funding

The trial was funded by the National Ministry of Science and Technology and the National Agency for Promotion of Science and Technology of Argentina.

Acknowledgments

We thank all the trial participants, the staff members at each site for their high degree of professionalism in the conduct of the trial. We also thank the i2e3 Procomms team (Barcelona, Spain) and especially Sara Cervantes, Ph.D., for providing medical writing support during the manuscript preparation. We thank the administrative staff at University of San Martin and at INBIRS. We thank the support of the University of San Martin (UNSAM), the National Scientific and Technical Research Council (CONICET), National Ministry of Science and technology, the National Agency for promotion of Science and Technology of Argentina, the National Ministry of Health, the Ministry of Health of the Province of Buenos Aires and the National Administration of Drugs, Food and Medical Devices (ANMAT). We are thankful to the staff of the Pablo Cassará Laboratory for their essential contribution to the development, scaling, manufacturing, control, and stability studies of the clinical batches of antigens and vaccines. We thank Ethel Feleder and Karina E. Halabe from Clinical Pharma S.R.L. We thank Javier Mariarini from Hospital el Cruce -Florencio Varela, Buenos Aires, Argentina- and Fundación Huésped -CABA, Argentina- for statistical analysis. We are grateful to Dr. Ángela Spanguolo de Gentile, Dr. Roberto Debbag, and Dr. Lucas Giménez who were members of the external Independent Committee of Data Review for their dedication and continuous invaluable advice.

Laboratorio Pablo Cassar Group for ARVAC: Sabrina A. Del Priore; Andrs C. Hernando Insua; Ingrid G Kaufman; Adrin Di Mara; Adrin Gongora; Agustin Moreno; Susana Cervellini; Martin Blasco; Fernando Toneguzzo.

References

1. Sarker R, Roknuzzaman ASM, Nazmunnahar, Shahriar M, Hossain MJ, Islam MR. The WHO has declared the end of pandemic phase of COVID-19: Way to come back in the normal life. Health Sci Rep [Internet] 2023 [cited 2024 Feb 12];6(9). Available from: <https://pubmed.ncbi.nlm.nih.gov/37674622/>
2. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic [Internet]. 2023 [cited 2024 Feb 12]; Available from: [https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-\(2005\)-emergency-committee-regarding-the-coronavirus-disease-\(covid-19\)-pandemic?adgroupsurvey=%7Badgroupsurvey%7D%26gclid=EAIaIQobChMI4Ojtsdbe_gIVjQRyCh07igt4EAAYASACEgJ9pfD_BwE%26fbclid=IwAR2M8EAyiSrAodhK9p-X582nHkP2AigpSX8pYIsLsPwqYh4SG26RGokGe7E](https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic?adgroupsurvey=%7Badgroupsurvey%7D%26gclid=EAIaIQobChMI4Ojtsdbe_gIVjQRyCh07igt4EAAYASACEgJ9pfD_BwE%26fbclid=IwAR2M8EAyiSrAodhK9p-X582nHkP2AigpSX8pYIsLsPwqYh4SG26RGokGe7E)
3. Roknuzzaman ASM, Sarker R, Nazmunnahar, Shahriar M, Mosharrafa R Al, Islam MR. The WHO has Declared COVID-19 is No Longer a Pandemic-Level Threat: A Perspective Evaluating Potential Public Health Impacts. Clinical Pathology [Internet] 2024 [cited 2024 Feb 12];17. Available from: </pmc/articles/PMC10804921/>
4. Andrews N, Tessier E, Stowe J, et al. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med [Internet] 2022 [cited 2024 Feb 13];386(4):340–50. Available from: </pmc/articles/PMC8781262/>
5. Chi WY, Li Y Der, Huang HC, et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune

- correlates of protection. *Journal of Biomedical Science* 2022 29:1 [Internet] 2022 [cited 2024 Feb 12];29(1):1–27. Available from: <https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-022-00853-8>
6. Focosi D, Quiroga R, McConnell S, Johnson MC, Casadevall A. Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. *Int J Mol Sci* [Internet] 2023 [cited 2024 Feb 12];24(3). Available from: <https://pubmed.ncbi.nlm.nih.gov/36768588/>
 7. World Health Organization (WHO). WHO SAGE Roadmap for prioritizing uses of COVID-19 vaccines: An approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios. [Internet]. 2023 [cited 2024 Feb 12]; Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.1>
 8. Uddin MN, Roni MA. Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines. *Vaccines (Basel)* [Internet] 2021 [cited 2024 Feb 13];9(9). Available from: [/pmc/articles/PMC8473088/](https://pubmed.ncbi.nlm.nih.gov/358473088/)
 9. Hotez PJ, Bottazzi ME. Developing a low-cost and accessible COVID-19 vaccine for global health. *PLoS Negl Trop Dis* [Internet] 2020 [cited 2024 Feb 13];14(7):1–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/32726304/>
 10. Bayani F, Hashkavaei NS, Arjmand S, et al. An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines. *Prog Biophys Mol Biol* 2023;178:32–49.
 11. Marchese AM, Beyhaghi H, Orenstein WA. With established safe and effective use, protein vaccines offer another choice against COVID-19. *Vaccine* [Internet]

- 2022 [cited 2024 May 6];40(46):6567. Available from: [/pmc/articles/PMC9515329/](https://pubmed.ncbi.nlm.nih.gov/38307851/)
12. National Administration of Drugs F and MT (Administración N de MA y TM). Disposition DI-2023-8604-APN-ANMAT#MS. Argentina: 2023.
 13. Coria LM, Rodriguez JM, Demaria A, et al. A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection. *Nat Commun* [Internet] 2024 [cited 2024 Feb 26];15(1):997. Available from: <https://pubmed.ncbi.nlm.nih.gov/38307851/>
 14. Pasquevich KA, Coria LM, Ceballos A, et al. Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults. *Nat Commun* [Internet] 2023 [cited 2024 Jan 31];14(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/37507392/>
 15. World Health Organization (WHO). WHO manual for the establishment of national and other secondary standards for antibodies against infectious agents focusing on SARS-CoV2. 2022;
 16. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat Med* [Internet] 2021 [cited 2024 Feb 5];27(11):2032–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/34588689/>
 17. US Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007.

18. de Bruyn G, Wang J, Purvis A, et al. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study. 2023 [cited 2024 Feb 13]; Available from: www.thelancet.com
19. Bennett C, Woo W, Bloch M, et al. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial. *Lancet Infect Dis* [Internet] 2024 [cited 2024 Mar 19]; Available from: <https://pubmed.ncbi.nlm.nih.gov/38460525/>
20. Corominas J, Garriga C, Prenafeta A, et al. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. *The Lancet regional health Europe* [Internet] 2023 [cited 2024 Mar 19];28. Available from: <https://pubmed.ncbi.nlm.nih.gov/37131861/>
21. Nolan TM, Deliyannis G, Griffith M, et al. Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster. *EBioMedicine* [Internet] 2023 [cited 2024 Feb 26];98. Available from: <https://pubmed.ncbi.nlm.nih.gov/38016322/>
22. Vacunas contra el SARS-CoV-2 | Argentina.gob.ar [Internet]. [cited 2024 Apr 23]; Available from: <https://www.argentina.gob.ar/anmat/covid-19-acciones/vacunas>

23. Sapkota B, Saud B, Shrestha R, et al. Heterologous prime-boost strategies for COVID-19 vaccines. *J Travel Med* [Internet] 2022 [cited 2024 Mar 18];29(3). Available from: <https://pubmed.ncbi.nlm.nih.gov/34918097/>
24. Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. *The Lancet* 2022;399(10324):521–9.
25. Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J. Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* 2022;19(17).
26. World Health Organization (WHO). Tracking SARS-CoV-2 variants [Internet]. [cited 2024 Feb 26]; Available from: <https://www.who.int/activities/tracking-SARS-CoV-2-variants>
27. Interim Statement on COVID-19 vaccines in the context of the circulation of the Omicron SARS-CoV-2 Variant from the WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) [Internet]. [cited 2024 Mar 18]; Available from: <https://www.who.int/news/item/11-01-2022-interim-statement-on-covid-19-vaccines-in-the-context-of-the-circulation-of-the-omicron-sars-cov-2-variant-from-the-who-technical-advisory-group-on-covid-19-vaccine-composition>
28. Actualización sobre el coronavirus (COVID-19): La FDA recomienda la inclusión de componente de ómicron BA.4/5 para las dosis de refuerzo de la vacuna contra el COVID-19 | FDA [Internet]. [cited 2024 Mar 19]; Available from:

<https://www.fda.gov/news-events/press-announcements/actualizacion-sobre-el-coronavirus-covid-19-la-fda-recomienda-la-inclusion-de-componente-de-omicron>

Tables

Table 1. Characteristics of study participants according to study Phase and sex. N=2012

| | Phase II | | | Phase III | | | All | | |
|---|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| | Female | Male | Total | Female | Male | Total | Female | Male | Total |
| N (%) | 134 (57.8) | 98 (42.2) | 232 | 834 (46.9) | 946 (53.1) | 1780 | 968 (48.1) | 1044 (51.9) | 2012 (100) |
| Age (years), mean (SD) | 36.6 (12.1) | 35.7 (11.5) | 36.2 (11.8) | 47.3 (16.7) | 52.0 (16.3) | 49.8 (16.6) | 45.8 (16.6) | 50.5 (16.6) | 48.2 (16.7) |
| BMI (kg/m ²), mean (SD) | 27.0 (4.8) | 26.9 (4.1) | 27.0 (4.5) | 26.7 (4.6) | 27.4 (3.9) | 27.1 (4.2) | 26.8 (4.6) | 27.3 (3.9) | 27.1 (4.3) |
| Number of boosters after complete primary vaccination scheme, n (%) | | | | | | | | | |
| 0 | 46 (34.3) | 40 (40.8) | 86 (37.1) | 93 (11.2) | 113 (19.9) | 206 (11.6) | 139 (14.4) | 153 (14.7) | 293 (14.5) |
| 1 | 88 (65.7) | 58 (59.2) | 146 (62.9) | 538 (64.5) | 526 (55.6) | 1064 (59.8) | 626 (64.7) | 584 (55.9) | 1210 (60.1) |
| 2 | | | | 101 (12.1) | 166 (17.5) | 267 (15.0) | 101 (10.4) | 166 (15.9) | 267 (13.3) |
| 3 | | | | 102 (12.2) | 141 (14.9) | 243 (13.6) | 102 (10.5) | 141 (13.5) | 243 (12.1) |
| Time since last vaccination (months), | | | | | | | | | |
| mean (SD) | 13.2 (2.7) | 13.1 (3.2) | 13.2 (2.9) | 14.8 (4.1) | 14.4 (4.6) | 14.3 (4.4) | 14.3 (4.3) | 14.3 (4.5) | 14.1 (4.3) |
| Previous COVID-19, n (%) | | | | | | | | | |
| No | 87 (64.9) | 73 (74.5) | 160 (69.0) | 406 (48.7) | 557 (58.9) | 963 (54.1) | 493 (50.9) | 630 (60.3) | 1123 (55.8) |
| Yes | 47 (35.1) | 25 (25.5) | 72 (31.0) | 428 (51.3) | 389 (41.1) | 817 (45.9) | 475 (49.1) | 414 (39.7) | 889 (44.2) |
| Time since infection (months), | | | | | | | | | |
| mean (SD) | 20.4 (8.1) | 20.4 (9.6) | 20.4 (8.6) | 19.8 (9.0) | 20.8 (8.6) | 20.0 (8.7) | 19.8 (9.0) | 20.8 (8.6) | 20.0 (8.7) |
| Study treatment, n (%) | | | | | | | | | |
| Bivalent | | | | 139 (16.7) | 158 (16.7) | 297 (16.7) | 139 (14.3) | 158 (15.1) | 297 (14.8) |
| Gamma | 70 (52.2) | 46 (46.9) | 116 (50.0) | 136 (16.3) | 161 (17.1) | 297 (16.7) | 206 (21.3) | 207 (19.9) | 413 (20.5) |
| Omicron | | | | 144 (17.2) | 153 (16.2) | 297 (16.7) | 144 (14.9) | 153 (14.6) | 297 (14.8) |
| Placebo | 64 (47.8) | 52 (53.1) | 116 (50.0) | 415 (49.8) | 474 (50.1) | 889 (49.9) | 479 (49.5) | 526 (50.4) | 1005 (50.0) |

BMI, body mass index; SD, standard deviation.

Table 2. Seroconversion rates in Phase II (n=228) and Phase III (n=1053) participants for the different vaccine variants and age groups compared to placebo and a >75% reference.

| Study Phase and treatment | SARS-CoV-2 | Seroconversion rate (%) | 95%CI | P-value ^a vaccine vs. placebo | P-value ^b vaccine vs. >75% |
|---|--------------|-------------------------|------------|---|--|
| Phase II, n=228 | | | | | |
| Placebo, n=114 | Ancestral | 9.6 | 5.5, 16.5 | NA | NA |
| | Gamma | 18.4 | 12.4, 26.5 | NA | NA |
| | Omicron BA.5 | 10.5 | 6.1, 17.5 | NA | NA |
| ARVAC Gamma, n=114 | Ancestral | 87.7 | 80.4, 92.5 | <.0001 | .0004 |
| | Gamma | 90.4 | 83.5, 94.5 | <.0001 | <.0001 |
| | Omicron BA.5 | 84.2 | 76.4, 89.8 | <.0001 | .0017 |
| Phase III all participants, n=1053 | | | | | |
| Placebo, n= 264 | Ancestral | 12.5 | 9.0, 17.0 | NA | NA |
| | Gamma | 12.1 | 8.7, 16.6 | NA | NA |
| | Omicron BA.5 | 15.2 | 11.3, 20.0 | NA | NA |
| ARVAC Gamma, n=265 | Ancestral | 86.8 | 82.2, 90.3 | <.0001 | <.0001 |
| | Gamma | 84.2 | 79.3, 88.1 | <.0001 | .0006 |
| | Omicron BA.5 | 81.9 | 76.8, 86.1 | <.0001 | .0105 |
| ARVAC Omicron BA.5, n=265 | Ancestral | 80.0 | 74.8, 84.4 | <.0001 | .0694 |
| | Gamma | 82.3 | 77.2, 86.4 | <.0001 | .0031 |
| | Omicron BA.5 | 87.5 | 83.0, 91.0 | <.0001 | <.0001 |
| ARVAC bivalent, n=259 | Ancestral | 92.7 | 88.8, 95.3 | <.0001 | <.0001 |
| | Gamma | 91.1 | 87.0, 94.0 | <.0001 | <.0001 |
| | Omicron BA.5 | 92.7 | 88.8, 95.3 | <.0001 | <.0001 |
| Phase III, participants 18-60 years | | | | | |
| Placebo, n= 158 | Ancestral | 7.6 | 4.4, 12.8 | NA | NA |
| | Gamma | 9.5 | 5.8, 15.1 | NA | NA |
| | Omicron BA.5 | 13.3 | 8.9, 19.5 | NA | NA |
| ARVAC Gamma, n=156 | Ancestral | 89.1 | 83.2, 93.1 | <.0001 | <.0001 |
| | Gamma | 89.1 | 83.2, 93.1 | <.0001 | <.0001 |
| | Omicron BA.5 | 86.5 | 80.3, 91.0 | <.0001 | .0009 |
| ARVAC Omicron BA.5, n=157 | Ancestral | 81.5 | 74.7, 86.8 | <.0001 | .0589 |
| | Gamma | 87.3 | 81.1, 91.6 | <.0001 | .0004 |
| | Omicron BA.5 | 87.3 | 81.1, 91.6 | <.0001 | .0004 |
| ARVAC bivalent, n=157 | Ancestral | 93.6 | 88.7, 96.5 | <.0001 | <.0001 |
| | Gamma | 91.7 | 86.3, 95.1 | <.0001 | <.0001 |
| | Omicron BA.5 | 93.0 | 87.9, 96.0 | <.0001 | <.0001 |
| Phase III, participants >60 years | | | | | |
| Placebo, n= 106 | Ancestral | 19.8 | 13.3, 28.4 | NA | NA |

| | | | | | |
|------------------------------|--------------|------|------------|--------|--------|
| | Gamma | 16.0 | 10.3, 24.2 | NA | NA |
| | Omicron BA.5 | 17.9 | 11.8, 26.3 | NA | NA |
| ARVAC Gamma, n=109 | Ancestral | 83.5 | 75.4, 89.3 | <.0001 | .0407 |
| | Gamma | 77.1 | 68.3, 84.0 | <.0001 | .6187 |
| | Omicron BA.5 | 75.2 | 66.4, 82.4 | <.0001 | .9559 |
| ARVAC Omicron BA.5, n=108 | Ancestral | 77.8 | 69.1, 84.6 | <.0001 | .5050 |
| | Gamma | 75.0 | 66.1, 82.2 | <.0001 | >.9999 |
| | Omicron BA.5 | 88.0 | 80.5, 92.8 | <.0001 | .0019 |
| ARVAC Bivalent, n=102 | Ancestral | 91.2 | 84.1, 95.3 | <.0001 | .0002 |
| | Gamma | 90.2 | 82.9, 94.6 | <.0001 | .0004 |
| | Omicron BA.5 | 92.2 | 85.3, 96.0 | <.0001 | <.0001 |

^aChi-square test for Phase II and Fisher's exact test for Phase III

^bZ-test

CI, confidence interval; NA, not applicable.

Table 3. Local and systemic adverse reactions according to severity and treatment (vaccine vs. placebo), n (%). N=2012

| | Vaccine (n=1960) | | | | | Placebo (n=1957) | | | | <i>P</i> -value** |
|--------------------------------|------------------|-----------|---------|---------|-------------------|------------------|-----------|---------|-------------------|-------------------|
| | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total* | Grade 1 | Grade 2 | Grade 3 | Total* | |
| Local, n (%)# | | | | | | | | | | |
| <i>Pain</i> | 810 (96.3) | 31 (3.7) | 0 | 0 | 841 (42.9) | 601 (98.0) | 11 (1.8) | 1 (0.2) | 613 (31.3) | <.001 |
| <i>Sensitivity/discomfort</i> | 565 (88.6) | 69 (10.8) | 4 (0.6) | 0 | 638 (32.5) | 385 (92.1) | 30 (7.2) | 2 (0.5) | 417 (21.3) | <.001 |
| <i>Swelling/induration</i> | 155 (98.1) | 3 (1.9) | 0 | 0 | 158 (8.1) | 73 (100) | 0 | 0 | 73 (3.8) | .257 |
| <i>Erythema/redness</i> | 74 (96.1) | 3 (3.9) | 0 | 0 | 77 (3.9) | 44 (97.8) | 1 (2.2) | 0 | 45 (2.3) | .660 |
| <i>Itching</i> | 54 (100) | 0 | 0 | 0 | 54 (2.8) | 28 (96.6) | 1 (3.4) | 0 | 29 (1.5) | .995 |
| Systemic, n (%)# | | | | | | | | | | |
| <i>Diarrhea</i> | 43 (91.5) | 3 (6.4) | 1 (2.1) | 0 | 47 (2.4) | 38 (97.4) | 1 (2.6) | 0 | 39 (2.0) | .388 |
| <i>Headache</i> | 203 (83.9) | 37 (15.3) | 2 (0.8) | 0 | 242 (12.3) | 170 (90.4) | 17 (9.0) | 1 (0.5) | 188 (9.6) | .006 |
| <i>Joint pain</i> | 48 (85.7) | 7 (12.5) | 1 (1.8) | 0 | 56 (2.9) | 39 (84.8) | 7 (15.2) | 0 | 46 (2.4) | .321 |
| <i>Muscle pain/myalgia</i> | 103 (86.6) | 15 (12.6) | 1 (0.8) | 0 | 119 (6.1) | 93 (86.9) | 14 (13.1) | 0 | 107 (5.5) | .420 |
| <i>Chills</i> | 34 (81.0) | 7 (16.7) | 1 (2.4) | 0 | 42 (2.1) | 26 (89.7) | 3 (10.3) | 0 | 29 (1.5) | .122 |
| <i>Fatigue/tiredness/decay</i> | 206 (88.8) | 23 (9.9) | 2 (0.9) | 1 (0.4) | 232 (11.8) | 169 (89.9) | 19 (10.1) | 0 | 188 (9.6) | .024 |
| <i>Fever</i> | 22 (75.9) | 6 (20.7) | 1 (3.4) | 0 | 29 (1.5) | 14 (93.3) | 1 (6.7) | 0 | 15 (0.8) | .034 |
| <i>Nausea</i> | 32 (94.1) | 2 (5.9) | 0 | 0 | 34 (1.7) | 31 (91.2) | 3 (8.8) | 0 | 34 (1.7) | .993 |
| <i>Palpitations</i> | 15 (83.3) | 3 (16.7) | 0 | 0 | 18 (0.9) | 12 (92.3) | 1 (7.7) | 0 | 13 (0.7) | .370 |
| <i>Drowsiness</i> | 196 (88.3) | 24 (10.8) | 2 (0.9) | 0 | 222 (11.3) | 183 (92.0) | 16 (8.0) | 0 | 199 (10.2) | .243 |
| <i>Vomiting</i> | 6 (100) | 0 | 0 | 0 | 6 (0.3) | 3 (50.0) | 3 (50.0) | 0 | 6 (0.3) | .997 |

Adverse reactions to all vaccine and placebo administrations are included.

#The percentage next to each grade was calculated over the total number of cases for each adverse reaction.

*Percentage of each adverse reaction calculated over the total number of administrations.

**Chi-square test.

Figures




Figure 1. Flow chart of study participants.




Figure 2. Neutralizing antibody titers against SARS-CoV-2 variants before (d1) and 14 days after vaccine/placebo administration. The plots represent antibody titers against SARS-CoV-2 Ancestral (A, D, G,

J), Gamma (B, E, H, K), and Omicron variants (C, F, I, L) in plasma samples of Phase II (A-C) and Phase III (D-F) participants. Phase III participants were classified according to age into 18-60 years (G-I) and >60 years (J-L). The thick horizontal lines in the violin plots represent median. Geometric mean titers (GMTs) value is indicated above the plots. Geometric mean fold rises (GMFR) and *p*-values comparing titers before and after administration are indicated. *P*-values were calculated using the non-parametric paired Wilcoxon test. nAb, neutralizing antibodies.